# Aspen RxHealth

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aspen-rxhealth

- Industry: Internet
- Headquarters: Tampa, US
- Website: www.aspenrxhealth.com
- Total disclosed funding: $32M
- Latest round: Series B (Jan 7, 2021)
- Investors on record: 6

## About

Aspen RxHealth is a healthcare technology company that specializes in transforming clinical pharmacy services through its innovative BeWell platform, enhancing medication management and patient outcomes for healthcare organizations.Aspen RxHealth, founded in 2018, is headquartered in Tampa, US. The company focuses on providing clinical pharmacy services through its BeWell platform. Wuhong Li is one of the founders, while David Medvedeff serves as the CEO. In January 2021, the company raised USD 23.00 mn in a Series B funding round led by Bessemer Venture Partners, with participation from dRx Capital, McKesson Ventures, and Takeda Pharmaceutical, as well as returning investors Flare Capital Partners and Humana Inc. This funding brought the total amount raised by Aspen RxHealth to USD 23.00 mn.Aspen RxHealth specializes in transforming clinical pharmacy services through its flagship offering, the BeWell platform. This flexible, web-based solution enables healthcare organizations to deliver a range of CMS-compliant clinical services, including Medication Therapy Management (MTM), Medication Adherence Programs, Chronic Disease Management, and Medication Reconciliation. By leveraging a nationwide network of licensed pharmacists, Aspen RxHealth aims to improve medication management, enhance patient outcomes, and reduce healthcare costs. The platform is designed to facilitate high-quality consultations at scale, making it suitable for health plans looking to optimize their clinical services. The company's solutions are primarily marketed to healthcare organizations across various regions in the United States, where they address gaps in patient care and medication management.Aspen RxHealth generates revenue by providing its BeWell platform as a service to healthcare organizations, which can either utilize their network of pharmacists or deploy their in-house care teams. The company’s transaction structure operates on a subscription model, where health plans pay for access to the platform and the associated clinical services. This includes pricing that reflects the volume of consultations or the scale at which services are deployed. The revenue model emphasizes B2B transactions, focusing on partnerships with health plans that seek to enhance their clinical offerings. The comprehensive nature of Aspen RxHealth's services is designed to foster long-term engagements with its clients, positioning the company as a valuable partner in the healthcare landscape.Aspen RxHealth plans to utilize the recent USD 23.00 mn raised in Series B funding to enhance its BeWell platform and expand its offerings. The company is exploring new product features tailored for specific clinical needs, which are expected to launch by mid-2022. Additionally, Aspen RxHealth aims to expand its services into new markets across the United States, targeting regions with identified gaps in clinical pharmacy services by the end of 2023. The funding will support these initiatives, allowing the company to scale its operations and increase its market presence.

## Funding rounds

- Series B, Jan 7, 2021, $23M — Bessemer Venture Partners, Humana Inc, McKesson Ventures, dRx Capital, Takeda Pharmaceutical, Flare Capital Partners
- Series A, Dec 12, 2018, $9M — Flare Capital Partners

## Investors

- Flare Capital Partners (https://capitalatlas.ai/funds/flare-capital-partners) — Series A, Series B
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B
- Humana Inc — Series B
- McKesson Ventures (https://capitalatlas.ai/funds/mckesson-ventures) — Series B
- dRx Capital (https://capitalatlas.ai/funds/drx-capital) — Series B
- Takeda Pharmaceutical — Series B